What bioavailability means
When a drug or compound is administered, not all of it necessarily reaches the bloodstream in active form. Bioavailability (often symbolised F) is the fraction of an administered dose that reaches systemic circulation unchanged. An intravenous injection has 100% bioavailability by definition - the substance goes directly into blood. Oral administration typically achieves lower bioavailability because the compound must survive digestion, absorption through the gut wall, and first-pass metabolism in the liver before reaching systemic circulation.
For most research peptides, oral bioavailability is very low - often below 1%. The biological barriers that prevent oral absorption of peptides are the same systems that have evolved to break down dietary protein.
The digestive barrier
The gastrointestinal tract is optimized to digest proteins. Proteolytic enzymes begin working in the stomach: pepsin cleaves peptide bonds between aromatic amino acids. In the small intestine, proteases from the pancreas (trypsin, chymotrypsin, elastase) continue degradation. Peptidases on the brush border of intestinal epithelial cells break peptides further into di- and tripeptides or individual amino acids.
This process is extraordinarily efficient - it has to be, because dietary protein must be broken into amino acids for absorption. It does not distinguish between nutritional proteins and research peptides. A peptide administered orally encounters the full force of this degradation machinery.
The small number of peptides that survive this process are typically very short (dipeptides and tripeptides can be absorbed via specific transporters) or have structures resistant to protease cleavage.
The intestinal wall barrier
Even if a peptide survived proteolytic digestion, it would face a second barrier: crossing the intestinal epithelium. The gut wall is designed to allow small molecules and specific nutrients through while excluding large molecules. Peptides above a few amino acids in length are generally too large and too hydrophilic (water-attracting) to passively diffuse through epithelial cell membranes.
Transcellular transport (through cells) requires specific transport proteins, most of which are designed for nutrients rather than synthetic peptides. Paracellular transport (between cells) is restricted by tight junctions. The result is poor absorption even for peptides that survive digestion intact.
First-pass metabolism
If a peptide were absorbed through the gut wall intact, it would still face first-pass metabolism: blood from the intestine drains directly to the liver via the portal vein before entering systemic circulation. The liver is rich in peptidases and other metabolic enzymes. Many compounds are substantially degraded in this first pass through the liver.
Routes that bypass the gut
Research peptide administration routes are chosen specifically to bypass these barriers:
Subcutaneous injection: The peptide is deposited under the skin, where it is absorbed directly into the lymphatic system and then systemic circulation, bypassing digestion entirely. This is the most common route for research peptides.
Intramuscular injection: Absorbed via capillaries in muscle tissue, also bypassing the gut.
Intranasal administration: A small number of peptides - particularly those with central nervous system targets - can cross the nasal mucosa and reach the CNS via the olfactory pathway. Bioavailability via this route is still low for most peptides but higher than oral.
Oral peptide drug development
Pharmaceutical research has invested substantially in overcoming oral bioavailability limitations. Strategies include encapsulation in lipid nanoparticles, conjugation to absorption-enhancing molecules, structural modification with non-natural amino acids to resist proteases, and cyclization. Semaglutide (a GLP-1 receptor agonist) became one of the first large-peptide drugs to achieve meaningful oral bioavailability through co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which transiently increases local pH in the stomach and enhances absorption across the gastric mucosa.
References: Vlieghe P et al. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010. Brayden DJ et al. Oral delivery of peptide therapeutics. Drug Discov Today. 2020. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018.
What bioavailability means
When a drug or compound is administered, not all of it necessarily reaches the bloodstream in active form. Bioavailability (often symbolised F) is the fraction of an administered dose that reaches systemic circulation unchanged. An intravenous injection has 100% bioavailability by definition - the substance goes directly into blood. Oral administration typically achieves lower bioavailability because the compound must survive digestion, absorption through the gut wall, and first-pass metabolism in the liver before reaching systemic circulation.
For most research peptides, oral bioavailability is very low - often below 1%. The biological barriers that prevent oral absorption of peptides are the same systems that have evolved to break down dietary protein.
The digestive barrier
The gastrointestinal tract is optimized to digest proteins. Proteolytic enzymes begin working in the stomach: pepsin cleaves peptide bonds between aromatic amino acids. In the small intestine, proteases from the pancreas (trypsin, chymotrypsin, elastase) continue degradation. Peptidases on the brush border of intestinal epithelial cells break peptides further into di- and tripeptides or individual amino acids.
This process is extraordinarily efficient - it has to be, because dietary protein must be broken into amino acids for absorption. It does not distinguish between nutritional proteins and research peptides. A peptide administered orally encounters the full force of this degradation machinery.
The small number of peptides that survive this process are typically very short (dipeptides and tripeptides can be absorbed via specific transporters) or have structures resistant to protease cleavage.
The intestinal wall barrier
Even if a peptide survived proteolytic digestion, it would face a second barrier: crossing the intestinal epithelium. The gut wall is designed to allow small molecules and specific nutrients through while excluding large molecules. Peptides above a few amino acids in length are generally too large and too hydrophilic (water-attracting) to passively diffuse through epithelial cell membranes.
Transcellular transport (through cells) requires specific transport proteins, most of which are designed for nutrients rather than synthetic peptides. Paracellular transport (between cells) is restricted by tight junctions. The result is poor absorption even for peptides that survive digestion intact.
First-pass metabolism
If a peptide were absorbed through the gut wall intact, it would still face first-pass metabolism: blood from the intestine drains directly to the liver via the portal vein before entering systemic circulation. The liver is rich in peptidases and other metabolic enzymes. Many compounds are substantially degraded in this first pass through the liver.
Routes that bypass the gut
Research peptide administration routes are chosen specifically to bypass these barriers:
Subcutaneous injection: The peptide is deposited under the skin, where it is absorbed directly into the lymphatic system and then systemic circulation, bypassing digestion entirely. This is the most common route for research peptides.
Intramuscular injection: Absorbed via capillaries in muscle tissue, also bypassing the gut.
Intranasal administration: A small number of peptides - particularly those with central nervous system targets - can cross the nasal mucosa and reach the CNS via the olfactory pathway. Bioavailability via this route is still low for most peptides but higher than oral.
Oral peptide drug development
Pharmaceutical research has invested substantially in overcoming oral bioavailability limitations. Strategies include encapsulation in lipid nanoparticles, conjugation to absorption-enhancing molecules, structural modification with non-natural amino acids to resist proteases, and cyclization. Semaglutide (a GLP-1 receptor agonist) became one of the first large-peptide drugs to achieve meaningful oral bioavailability through co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which transiently increases local pH in the stomach and enhances absorption across the gastric mucosa.
References: Vlieghe P et al. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010. Brayden DJ et al. Oral delivery of peptide therapeutics. Drug Discov Today. 2020. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018.
